{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:27:06Z","timestamp":1790645226951,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013987","name":"Government of the Republic of Kenya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013987","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005864","name":"National Commission for Science, Technology and Innovation","doi-asserted-by":"publisher","award":["NACOSTI\/RCD\/ST&I 6th CALL MSc 055"],"award-info":[{"award-number":["NACOSTI\/RCD\/ST&I 6th CALL MSc 055"]}],"id":[{"id":"10.13039\/501100005864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019734","name":"Kenya Medical Research Institute","doi-asserted-by":"publisher","award":["01\/10\/2018"],"award-info":[{"award-number":["01\/10\/2018"]}],"id":[{"id":"10.13039\/501100019734","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ijantimicag.2023.107012","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T07:34:02Z","timestamp":1697787242000},"page":"107012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug selection pressure and fitness cost for artemether-resistant Plasmodium berghei ANKA parasites in vivo"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-8713","authenticated-orcid":false,"given":"Milka Wambui","family":"Waithera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Wekesa","family":"Sifuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1564-5579","authenticated-orcid":false,"given":"Shadrack Kanyoji","family":"Kimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.107012_bib0001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijpara.2016.05.008","article-title":"Out of Africa: origins and evolution of the human malaria parasites Plasmodium falciparum and Plasmodium vivax","volume":"47","author":"Loy","year":"2017","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0002","article-title":"Antiplasmodial activity assay of 3-chloro-4- (4-chlorophenoxy) aniline combinations with artesunate or chloroquine in vitro and in a mouse model","volume":"2019","author":"Sifuna","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0003","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00436-023-07801-x","article-title":"Antimalarial activity assay of artesunate-3-chloro-4(4-chlorophenoxy) aniline in vitro and in mice models","volume":"122","author":"Waithera","year":"2023","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0004","article-title":"The future of the RTS,S\/AS01 malaria vaccine: an alternative development plan","volume":"134","author":"Gosling","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (MosquirixTM): an overview","volume":"16","author":"Laurens","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0006","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/vaccines10050713","article-title":"MosquirixTM RTS, S\/AS01 vaccine development, immunogenicity, and efficacy","volume":"10","author":"Nadeem","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0007","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpddr.2021.05.007","article-title":"Plasmodium falciparum resistance to ACTs: emergence, mechanisms, and outlook","volume":"16","author":"Siddiqui","year":"2021","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0008","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/microbiolspec.EI10-0013-2016","article-title":"Artemisinin-resistant plasmodium falciparum malaria","volume":"4","author":"Fairhurst","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0009","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/QCO.0000000000000766","article-title":"Artemisinin and multidrug-resistant Plasmodium falciparum \u2013 a threat for malaria control and elimination","volume":"34","author":"Dhorda","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0010","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1365-3156.2007.01843.x","article-title":"The role of pfmdr1 in Plasmodium falciparum tolerance to artemether\u2013lumefantrine in Africa","volume":"12","author":"Sisowath","year":"2007","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0011","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/nyas.12766","article-title":"Antimalarial drug resistance in Africa: key lessons for the future","volume":"1342","author":"Takala-Harrison","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0012","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jgar.2021.09.001","article-title":"New insights into the spread of resistance to artemisinin and its analogues","volume":"27","author":"Noreen","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12936-019-2724-z","article-title":"The past, present and future of anti-malarial medicines","volume":"18","author":"Tse","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/5060665","article-title":"Drug development strategies for malaria: with the hope for new antimalarial drug discovery \u2013 an update","volume":"2023","author":"Pandey","year":"2023","journal-title":"Adv Med"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0015","doi-asserted-by":"crossref","first-page":"e01949","DOI":"10.1128\/AAC.01949-20","article-title":"Continued low efficacy of artemether-lumefantrine in Angola in 2019","volume":"65","author":"Dimbu","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2023.107012_bib0016","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1475-2875-8-S1-S5","article-title":"The clinical efficacy of artemether\/lumefantrine (Coartem\u00ae)","volume":"8","author":"Makanga","year":"2009","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4269\/ajtmh.20-0148","article-title":"State of artemisinin and partner drug susceptibility in plasmodium falciparum clinical isolates from Colombia","volume":"104","author":"Montenegro","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0018","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/femsre\/fuw037","article-title":"The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread","volume":"41","author":"Woodrow","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0019","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12936-015-1075-7","article-title":"Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa","volume":"15","author":"Slater","year":"2016","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0020","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","article-title":"Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study","volume":"21","author":"Uwimana","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0021","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.24072\/pcjournal.200","article-title":"Fitness costs and benefits in response to artificial artesunate selection in Plasmodium","volume":"2","author":"Villa","year":"2022","journal-title":"Peer Community J"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0022","doi-asserted-by":"crossref","first-page":"e57689","DOI":"10.1371\/journal.pone.0057689","article-title":"Reduced susceptibility of Plasmodium falciparum to artesunate in Southern Myanmar","volume":"8","author":"Kyaw","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0023","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.3201\/eid2404.170141","article-title":"Artemisinin-resistant Plasmodium falciparum with high survival rates, Uganda, 2014\u20132016","volume":"24","author":"Ikeda","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0024","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1471-4922(01)01899-2","article-title":"Of mice and malaria mutants: unravelling the genetics of drug resistance using rodent malaria models","volume":"17","author":"Carlton","year":"2001","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.exppara.2009.03.010","article-title":"Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model","volume":"122","author":"Kiboi","year":"2009","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5897\/AJBR2014.0780","article-title":"Plasmodium berghei ANKA: selection of pyronaridine resistance in mouse model","volume":"8","author":"Kimani","year":"2014","journal-title":"Afr J Biochem Res"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00436-003-1029-9","article-title":"Selection and reversal of Plasmodium berghei resistance in the mouse model following repeated high doses of artemether","volume":"92","author":"Xiao","year":"2004","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0028","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nrmicro2239","article-title":"Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria","volume":"7","author":"Eastman","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0029","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1098\/rstb.2003.1414","article-title":"Virulence in malaria: an evolutionary viewpoint","volume":"359","author":"Mackinnon","year":"2004","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0030","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1371\/journal.pbio.0020230","article-title":"Immunity promotes virulence evolution in a malaria model","volume":"2","author":"Mackinnon","year":"2004","journal-title":"PLoS Biol"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0031","doi-asserted-by":"crossref","first-page":"e21251","DOI":"10.1371\/journal.pone.0021251","article-title":"Resistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge cost of fitness","volume":"6","author":"Muregi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0032","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.pt.2009.07.003","article-title":"Virulence and drug resistance in malaria parasites","volume":"25","author":"Stein","year":"2009","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0033","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1475-2875-7-257","article-title":"Does the drug sensitivity of malaria parasites depend on their virulence?","volume":"7","author":"Schneider","year":"2008","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0034","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2958.2007.05753.x","article-title":"Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites","volume":"65","author":"Hunt","year":"2007","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0035","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature05913","article-title":"Perceptions of epigenetics","volume":"447","author":"Bird","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0036","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1074\/jbc.M806944200","article-title":"Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione","volume":"284","author":"Raj","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0037","doi-asserted-by":"crossref","first-page":"19914","DOI":"10.1073\/pnas.0707766104","article-title":"Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model","volume":"104","author":"Wargo","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0038","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1128\/AAC.50.2.480-489.2006","article-title":"Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10","volume":"50","author":"Afonso","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0039","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.00875-06","article-title":"Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria","volume":"51","author":"Humphreys","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107012_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009133","article-title":"Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea","volume":"16","author":"Miotto","year":"2020","journal-title":"PLoS Pathog"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T21:04:19Z","timestamp":1718658259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923002868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0924857923002868"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107012","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug selection pressure and fitness cost for artemether-resistant Plasmodium berghei ANKA parasites in vivo","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107012"}}